Indirubin derivative E804 inhibits angiogenesis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Shin, Eun Kyung ^a   Kim, Jin Kyung ^b  

^a Hallym University   (South Korea)

^b Catholic University of Daegu   (South Korea)

Author keywords

Angiogenesis; Human umbilical vein endothelial cells; Indirubin derivative E804; Tumor; Vascular endothelial growth factor receptor 2

Indexed keywords

CD31 ANTIGEN; E 804; INDOLE DERIVATIVE; KI 67 ANTIGEN; PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; MALE; MICE; MICROVESSELS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; SIGNAL TRANSDUCTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84860380244     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-164     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1):27-31. 10.1038/nm0195-27, 7584949.
3. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence?. Angiogenesis 2007, 10(3):149-166. 10.1007/s10456-007-9074-0, 17457680.
4. Risau W. Mechanisms of angiogenesis. Nature 1997, 386(6626):671-674.
5. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007, 16(1):83-107. 10.1517/13543784.16.1.83, 17155856.
6. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006, 13(2):63-69. 10.1080/10623320600697955, 16728325.
7. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol 2005, 9(4):777-794.
8. Shinkaruk S, Bayle M, Laïn G, Déléris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003, 3(2):95-117. 10.2174/1568011033353452, 12678905.
9. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007, 8(1):15-27. 10.1007/s11864-007-0022-4, 17634832.
10. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002, 43(9):1763-1768. 10.1080/1042819021000006295, 12685829.
11. Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 2001, 20(29):3786-3797. 10.1038/sj.onc.1204503, 11439342.
12. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J Biol Chem 2001, 276(1):251-260.
13. Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M, Greengard P, Meijer L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 2004, 47(4):935-946. 10.1021/jm031016d, 14761195.
14. Choi SJ, Lee JE, Jeong SY, Im I, Lee SD, Lee EJ, Lee SK, Kwon SM, Ahn SG, Yoon JH, Han SY, Kim JI, Kim YC. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem 2010, 53(9):3696-3706. 10.1021/jm100080z, 20361800.
15. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A 2005, 102(17):5998-6003. 10.1073/pnas.0409467102, 1087919, 15837920.
16. Basu P, Ghosh RN, Grove LE, Klei L, Barchowsky A. Angiogenic potential of 3-nitro-4-hydroxy benzene arsonic acid (roxarsone). Environ Health Perspect 2008, 116(4):520-523. 2290980, 18414637.
17. Vailhé B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Invest 2001, 81(4):439-452. 10.1038/labinvest.3780252, 11304563.
18. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5(6):423-435. 10.1038/nrc1628, 15928673.
19. Ali N, Yoshizumi M, Fujita Y, Izawa Y, Kanematsu Y, Ishizawa K, Tsuchiya K, Yano S, Sone S, Tamaki T. A novel Src kinase inhibitor, M475271 inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. J Pharmacol Sci 2005, 98(2):130-141. 10.1254/jphs.FP0040850, 15937404.
20. Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, Wu Y, Song Y, Luo J, Pang X, Yi Z, Liu M. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 2010, 31(12):2097-2104. 10.1093/carcin/bgq167, 20732905.
21. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl 3):4-10.
22. Alladina SJ, Song JH, Davidge ST, Hao C, Easton AS. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res 2005, 42(4):337-347. 10.1159/000086599, 15985761.
23. Berra E, Milanini J, Richard DE, Le Gall M, Viñals F, Gothié E, Roux D, Pagès G, Pouysségur J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000, 60(8):1171-1178. 10.1016/S0006-2952(00)00423-8, 11007955.
24. Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R, Bird D, Marshall CJ. ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 2006, 9(1):33-44. 10.1016/j.ccr.2005.12.021, 16413470.
25. Kim JK, Shin EK, Kang YH, Park JH. Indirubin-3'-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis. J Cell Biochem 2011, 112(5):1384-1391. 10.1002/jcb.23055, 21337385.
26. Zhang X, Song Y, Wu Y, Dong Y, Lai L, Zhang J, Lu B, Dai F, He L, Liu M, Yi Z. Indirubin inhibits tumor growth by anti-tumor angiogenesis through blocking VEGFR2 mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer 2011, 129(10):2502-2511. 10.1002/ijc.25909, 21207415.